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Background:We describe the genomic landscape of circulating tumour DNA (ctDNA) across pathological sub-
types of metastatic breast cancer.
Methods: 255 clinically annotated patients with ctDNA testing by Guardant360 were stratified into HR+,
HER2+, and TNBC cohorts. Frequency and heterogeneity of alterations were reported. Paired ctDNA and tis-
sue sequencing were compared for a subset of patients. The association of ctDNA and metastatic sites of dis-
ease on imaging was also assessed.
Findings: 89% of patients had at least one ctDNA alteration detected. The most common single nucleotide var-
iants (SNVs) for HR+ patients were PIK3CA, ESR1, and TP53. For HER2+, these were TP53, PIK3CA, and ERBB2
with ERBB2 as the most frequent copy number variant (CNV). For TNBC, the most common SNVs were TP53
and PIK3CA, and the most frequent CNVs were MYC, CCNE1, and PIK3CA. TNBC patients had a significantly
higher mutant allele frequency (MAF) of the highest variant compared to HR+ or HER2+ patients (P<0.05).
Overall, alterations in PIK3CA, ESR1, and ERBB2 were observed in 39.6%, 16.5%, and 21.6% of patients, respec-
tively. Agreement between blood and tissue was 7991%. MAF and number of alterations were significantly
associated with number of metastatic sites on imaging (P<0.0001).
Interpretation: These data demonstrate the genetic heterogeneity of metastatic breast cancer in blood, the
high prevalence of clinically actionable alterations, and the potential to utilise ctDNA as a surrogate for
tumour burden on imaging.
Funding: Lynn Sage Cancer Research Foundation, OncoSET Precision Medicine Program, and REDCap support
was funded by the National Institutes of Health UL1TR001422.
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Since the first report of extracellular nucleic acids detected in the
peripheral blood in 1948 to the eventual determination that cancer
patients had elevated concentrations in DNA that correlated with
oncogenic mutations in tissue, liquid biopsies continue to move
closer to patient care [1]. These circulating nucleic acids, which were
later coined circulating tumour DNA (ctDNA), formed the framework
for non-invasive detection of genomic alterations in the peripheral
blood. The potential clinical utility of ctDNA assessment has beenexplored across all stages of disease, including early detection, adju-
vant assessment of minimal residual disease, and treatment monitor-
ing and resistance with varying degrees of progress [28]. Given the
greater tumour volume, number of mutations, and clonal complexity
in advanced compared to early stage breast cancer, there is a critical
need to define the landscape of ctDNA in metastatic breast cancer.
Based on tissue analysis, there are defined differences in gene
expression across the four intrinsic molecular subtypes of early-stage
breast cancer: luminal A, luminal B, HER2-enriched, and basal-like
[9]. Further, particular genomic profiles confer prognostic informa-
tion in primary breast cancer [10,11]. Importantly, compared with
early stage breast cancer, metastatic breast cancer has greater geno-
mic complexity [12]. This complexity not only varies at baseline tis-
sue sequencing assessment, but specific genomic resistance
mutations can emerge in response to the selective pressure of treat-
ment. Examples include the development of ESR1 mutations for
Research in Context
Evidence before this study
Mutation profiling using tissue next-generation sequencing
(NGS) has been well characterised over the last two decades.
With the emergence of circulating tumour DNA (ctDNA) as a
non-invasive NGS method, there is a critical need to define the
mutational landscape in blood and to compare mutational pro-
files of metastatic breast cancer between blood and tissue. We
explored prior work using PubMed with the following terms:
“circulating tumour DNA,” “ctDNA,” and “metastatic breast can-
cer.” Several studies focused on particular resistance altera-
tions, such as PIK3CA or ESR1, which were identified in blood. A
few smaller studies compared tissue and blood NGS in meta-
static breast cancer. Robust clinical and imaging annotation
associated with ctDNA data are lacking in some studies. Fur-
thermore, ctDNA data analysed across breast cancer subtypes
(hormone-receptor positive, HER2 positive, and triple negative
breast cancer) are limited.
Added value of this study
Here, we present the results of a large (>250 patient), clinically
annotated cohort of patients with metastatic breast cancer who
underwent ctDNA evaluation. We report the mutational fre-
quencies across subtypes and the frequency of clinically mean-
ingful alterations in PIK3CA, ESR1, and ERBB2. Additionally,
there was relatively high agreement between blood and tissue
sequencing, and ctDNA content was significantly associated
with number of metastatic sites on imaging. These data rein-
force the capability of utilising ctDNA to detect tumour hetero-
geneity across breast cancer subtypes, the high prevalence of
clinically actionable alterations, and the association between
ctDNA and tumour burden on imaging.
Implications of all the available evidence
ctDNA reflects the tumour landscape in blood to accurately
reflect tumour heterogeneity across metastatic breast cancer
subtypes. Therefore, ctDNA could serve as a tool to characterise
genomic alterations non-invasively, to enrol patients onto tar-
geted precision medicine clinical trials, and to serve as a surro-
gate for tumour burden on imaging. Further studies are needed
to incorporate ctDNA assays into novel clinical trial designs for
patient enrolment and stratification and to compare dynamics
of serial genomic testing of metastatic breast cancer patients in
the blood.
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non-amplified disease, and RB1 loss, aberrant FGFR signalling, or
CCNE1 overexpression for patients treated with CDK4/6 inhibitors
[1219].
Liquid biopsies are non-invasive tools to explore tumour content
in the peripheral blood, including ctDNA, circulating tumour cells
(CTCs), exosomes, and/or proteins. Prior studies have explored the
concordance between genomic alterations detected in tissue and
blood with relatively high agreement, particularly at allele frequen-
cies greater than 1% [20]. There are some technical reasons to account
for differences, including spatial and temporal heterogeneity,
tumours that do not shed ctDNA, and clonal hematopoiesis of inde-
terminate potential (CHIP) [20,21]. Prior work has also demonstrated
that the amount of tumour released into in the blood increases with
stage and that both the detection and genomic heterogeneity of
ctDNA in blood correlate with worse clinical outcomes [2225].However, the precise degree with which ctDNA content correlates
with sites of disease on imaging remains understudied.
Here, we describe the genomic landscape of ctDNA in metastatic
breast cancer across pathological subtypes. We further report the
prevalence and heterogeneity of clinically actionable alterations,
including mutations in PIK3CA, ERBB2, and ESR1. In addition, we eval-
uate concordance between ctDNA and tissue next-generation
sequencing (NGS) for patients with paired sequencing. Finally, we
explore the utility of ctDNA assessment as a surrogate for tumour
burden on imaging. These analyses aim to define the potential clinical
utility of peripheral blood assessment of ctDNA to define the genomic
complexity of metastatic breast cancer.2. Materials and methods
2.1. Patient selection and study design
The Institutional Review Board (IRB) at the Robert H. Lurie Com-
prehensive Cancer Center of Northwestern University approved the
study. Requirement for informed consent was waived per the IRB for
this retrospective, de-identified analysis. Studies were performed in
concordance with the Health Insurance Portability and Accountability
Act and the Declaration of Helsinki. All patients with ctDNA NGS from
a single institution (Northwestern University, Chicago, IL) were retro-
spectively identified from 2015 to 2019. In total, 344 patients and
807 separate ctDNA tests (median 1 per patient) were found. Of
these, 255 patients were confirmed Stage IV disease by patient chart
review and included in the study. These 255 patients were consecu-
tively enroled in order to limit potential confounding effect. ctDNA
reports were reviewed for type and number of alterations, mutant
allele frequency (MAF), and timeframe of collection. MAF was defined
as the highest allele frequency variant in blood. For patients with
more than one blood collection, only the first ctDNA test was
included in this study. The electronic medical records were reviewed
for all patients and clinical annotation was performed and stored
using a secure REDCap database.2.2. ctDNA sequencing
ctDNA was evaluated using the commercially available Guar-
dant360 assay (Guardant Health, Inc., Redwood City, CA) to evaluate
up to 73 cancer-related genes, depending on the date of sequencing
[range 5473 genes] [26,27]. The NGS testing was performed in a
CLIA-certified and College of American Pathologists accredited labo-
ratory. ctDNA testing was performed as part of standard clinical care.
Two 10 mL of peripheral blood was collected in Streck Cell-Free DNA
BCT (Streck, Inc., La Vista, NE) for sample preparation with plasma
evaluated for single-nucleotide variants (SNVs), insertions-deletion
mutations (indels), fusions, and amplifications of both synonymous
and non-synonymous alterations. Previously, the platform was
reported to have analytic sensitivity below 0.1% allele fraction, sensi-
tivity of 85.9%, very high specificity (>99.9999%), and clinical
sequencing success rate of approximately 99.6% [27].2.3. Tissue NGS sequencing
Tissue NGS for comprehensive genomic profiling was performed
for standard of care and clinical trial enrolment using two commer-
cially available platforms: FoundationOne CDX (Foundation Medi-
cine, Cambridge, MA) or Tempus|xT (Tempus, Chicago, IL). After
identifying patients who had ctDNA sequencing, patients with both
blood and tissue NGS sequencing were analysed for concordance of
detected alterations. Only alterations that were covered in both
sequencing platforms were compared.
Table 1.
Patient characteristics. Shown are basic clinical, demographic, and patho-
logic characteristics for the entire cohort of patients with metastatic breast
cancer (N = 255). In addition, sites of disease on imaging in close proximity








HER2 positive 75 29.4




















Low (1 site) 74 29.0
High ( 2 sites) 181 70.0
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To assess ctDNA as a surrogate for tumour burden on imaging,
computed tomography (CT) or positive emission tomography (PET)-
CT radiographic reports were reviewed for patients included in the
study. The scan in closest proximity to the ctDNA collection date was
reviewed for number and sites of metastatic disease. MAF and num-
ber of detected ctDNA alterations were associated with metastatic
sites of disease detected on imaging. Metastatic sites were categor-
ised into the following: lung, liver, bone, lymph node, soft tissue, and
central nervous system. Each category was counted as a single meta-
static site (e.g. multiple lymph nodes involved counted as one site of
disease).
2.5. Statistical analysis
Clinical and pathological variables were reported using descrip-
tive analyses through frequencies for categorical variables or medians
and interquartile range (IQR) for continuous variables. The concor-
dance between alterations in blood and tissue was evaluated using
Cohen's kappa coefficient (k). Associations between ctDNA and sites
of disease on imaging and subtypes were tested using the Man-
nWhitney U or KruskalWallis as statistically appropriate. High
tumour burden defined as 2 or more sites of distant metastasis based
on imaging was associated with ctDNA and clinical characteristics
using uni- and multivariate logistic regression. Statistical analysis
was performed using STATA (StataCorp. (2019) Stata Statistical
Software: Release 14.2. College Station, TX: StataCorp LP), JMP (SAS
Institute Inc. (2019), version 14. Cary, NC), and R (R Core Team
(2019), version 3.6.2. R Foundation for Statistical Computing, Vienna,
Austria).
The funding sources had no role in the study design, data collec-
tion, data analysis, interpretation, or writing of the manuscript.
3. Results
3.1. Patient characteristics
A total of 255 patients with metastatic breast cancer at the time of
ctDNA collection were included in the study (Table 1). The median
age of patients in the cohort was 56 years. The cohort consisted of
254 females (99.6%) and 1 male (0.4%). The sample consisted of the
following: 124 HR+, HER2- (48.6%), 31 HR-, HER2+ (12.2%), 44 HR+,
HER2+ (17.3%), and 56 triple-negative breast cancer (TNBC) patients
(22.0%). For the majority of analyses, all HER2+ patients were com-
bined together, regardless of HR status. HR and HER2 status were
reassessed through biopsy of a metastatic lesion in 73% of patients.
Based on histology, there were 212 patients (83.1%) with invasive
ductal carcinoma (IDC), 22 patients (8.6%) with invasive lobular carci-
noma (ILC), 7 patients (2.7%) with mixed type, and the remaining 14
patients (5.5%) had unknown histology. Seventy-four patients (30.3%)
had inflammatory breast cancer. Median prior lines of treatment in
the metastatic setting at the time of ctDNA collection was 3 [IQR
15]. With respect to prior treatment, 39% of the patients had
received an aromatase inhibitor (AI), 27% had received AI or fulves-
trant combined with CDK4/6 inhibitor, and no patients had received
prior poly ADP ribose polymerase (PARP) inhibitor therapy.
3.2. ctDNA genomic alterations
The landscape of genomic alterations in the overall cohort is
shown in Fig. 1, including the genes with alterations, types of altera-
tions, and MAF of the highest variant in the blood. 227 patients (89%)
had at least one alteration or amplification detected. The median
number of alterations was 4 [IQR 1 to 7]. With respect to MAF of the
highest variant, the median was 3.8% [IQR 0.6% to 17.5%]. In total,alterations in 60 different genes were observed, as well as two
fusions. Across the entire cohort, the most common genes with alter-
ations observed in descending order of frequency were the following:
TP53 (189), PIK3CA (144), ERBB2 (77), ESR1 (75), MYC (57), EGFR (55),
FGFR1 (49), CCNE1 (42), NF1 (38), and ARID1A (35). CNVs were most
common for the following genes: MYC (52), FGFR1 (39), PIK3CA (37),
ERBB2 (36), CCNE1 (32), EGFR (31), CDK6 (25), BRAF (21), CCND1 (21).
Next, the landscape of alterations was evaluated by subtype
obtained from primary pathological reports (HR+, HER2+, or TNBC).
The 15 most frequent alterations by subtype were analysed. For HR+
breast cancer, the most common SNVs were PIK3CA (69), ESR1, (64)
and TP53 (58) (Fig. 2A). Median allele frequency was highest for
mutations in PIK3CA. For HER2+ breast cancer, SNVs were most com-
mon in TP53 (38), PIK3CA (23), and ERBB2 (15) with ERBB2 as the
most frequently encountered CNV in the cohort (33) (Fig. 2B). For
TNBC, the most commonly observed SNVs were TP53 (31) and
PIK3CA, (13) and the most frequently observed CNVs were MYC,
CCNE1, and PIK3CA (Fig. 2C). Median MAF for HR+, HER2+, and TNBC
subtypes were 3.5 (IQR 0.616.6), 2.6 (IQR 0.38.0), and 9.9
(1.327.7), respectively (P<0.05, Kruskal-Wallis equality-of-popula-
tions rank test). The landscape of alterations for HR+ vs HR- HER2+
disease is shown in Supplemental Fig. 1. No differences in number of
alterations were detected amongst the subtypes: HR+ (median 4, IQR
28), HER2+ (median 4.5, IQR 27), and TNBC (median 5, IQR 37).
3.3. Evaluation of clinically actionable ctDNA targets
Alterations in PIK3CA, ESR1, and ERBB2 were commonly encoun-
tered in the cohort at the following frequencies: 101 (39.6%), 42
(16.5%) and 55 (21.6%), respectively (Fig. 1). For the HR+ HER2-
cohort, 37 out of 123 (30.1%) patients had ESR1mutations. The detec-
tion of ESR1 mutations was significantly associated with prior use of
AI (P<0.001). With respect to ERBB2, 28 of 55 (50.9%) alterations
were amplifications and the remaining 27 of 55 (49.1%) were
Fig. 1. ctDNA landscape in metastatic breast cancer (N: 255). Shown is a heatmap of detected genomic alterations across the entire cohort. The y-axis includes alterations in
descending frequency with the most common alterations detected at the following frequencies: TP53 (189), PIK3CA (144), ERBB2 (77), ESR1 (75), MYC (57), EGFR (55), FGFR1 (49),
CCNE1 (42), NF1 (38), and ARID1A (35). The following variants were included on the x-axis from left to right: amplifications (ampl), copy number variants (CNV), fusions (fus), dele-
tions (del), insertions (ins), frameshift (fs), splicing variants (Spl), premature termination codons (PTC), and single nucleotide variants (SNV). Boxplots including the interquartile
range and outliers for allele frequency are included. Each row represents a gene. A heatmap scale is included in the lower right corner.
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with amplifications occurred in HER2+ patients. Notably, one amplifi-
cation was observed in a HR+ HER2- patient. In contrast, for muta-
tions in ERBB2, 16 were observed in HR+ HER2- (16 of 17 ERBB2
alterations, 94.1%), 8 were encountered in HER2+ patients (8 of 35
ERBB2 alterations, 22.9%), and 3 mutations were found in TNBC
patients (3 of 3 ERBB2 alterations, 100%). Importantly, the diversity of
alterations detected in the population was broad. In total, 34 unique
SNVs were detected in PIK3CA, 31 different SNVs in ERBB2, and 17 dif-
ferent SNVs in ESR1 (Fig. 3). The 3 most common alterations observed
in PIK3CA were amplification, H1047R, and E542K. For ERBB2, theseincluded amplification, S310F, and V777L. Finally, the 3 most com-
monly encountered alterations in ESR1 were D538G, Y537S, and
Y537N. No amplifications were detected in ESR1.
Notably, 6 patients had 2 concomitant ESR1 alterations, while 8
patients had 3 or more alterations (Supplemental Table 1). In addi-
tion, 30 patients had more than one concomitant PIK3CA alteration,
including 15 patients with an amplification combined with an SNV
with the remaining patients having multiple SNVs
(Supplemental Table 1). Although frequent amplifications were seen
in ERBB2, 5 out of 10 patients with concomitant ERBB2 alterations
showed a combination of SNVs (Supplemental Table 1).
Fig. 2. AC Landscape of alterations for the 15 most common alterations by pathological subtype (HR+, HER2+, TNBC) (N: 255). Shown is a heatmap of detected alterations with
similar design as compared to Fig. 1 for the following cohorts: HR+ (N: 124, Panel A), HER2+ (N: 75, Panel B), and TNBC (N: 56, Panel C). The 5 most common alterations by subtype
included PIK3CA (84), TP53 (77), ESR1 (64), FGFR1 (33), and ERBB2 (24) for HR+, TP53 (52), ERBB2 (48), PIK3CA (33), MYC (15), EGFR (15) for HER2+, and TP53 (55), PIK3CA (26), MYC
(20), CCNE1 (19), and EGFR (17) for TNBC.
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Concordance of genomic alterations was compared between
blood and tissue for the 10 most commonly observed alterations
in the cohort. Genes were only analysed if the particular gene was
sequenced in both NGS panels. In total, 105 patients had blood
and tissue sequencing in the cohort (54 with Foundation testing,
44 with Tempus testing, 7 with both platforms). Median timeframe
between sample collections was 12 weeks (IQR 2.564.3) (Table 2).
A moderate to high concordance was observed for alterations in
TP53 and PIK3CA with a Cohen kappa of 0.5809 and 0.5513, respec-
tively (observed agreement 79.1% and 81.0%, respectively)
(Table 2). A higher observed agreement (90.5%) was observed for
FGFR1 with a kappa of 0.6313. PIK3CA alterations were detected in
tissue, but not ctDNA in 7.6% of cases, while 11.4% of cases were
detected in ctDNA only. ERBB2 was discordant in 21% of samples.
ESR1 alterations were detected based on tissue biopsy alone in
3.8% of cases, while in 11.4% of cases an alteration was detected in
ctDNA, but not tissue.3.5. Comparison of ctDNA with imaging evaluation
For all patients with available imaging in close proximity to ctDNA
evaluation (N = 255), ctDNA MAF of the highest variant and number
of detected alterations were associated with the number of meta-
static sites observed on imaging (CT or PET-CT). The median time-
frame between blood and imaging analysis was 1.6 weeks (IQR 0.71 -
4.57). Sites of metastatic disease were binned into the following
groups: 0, 1, 2, 3, 4, 5. Higher MAF in ctDNA was significantly associ-
ated with a greater number of metastatic sites on imaging in an incre-
mental manner (Mann Whitney U test, P<0.0001) (Fig. 4A). Similarly,
a significant finding was observed when analysing the number of
detected alterations in ctDNA compared with sites of disease (Mann
Whitney U test, P<0.0001) (Fig. 4B), further indicating an association
between ctDNA tumour content and heterogeneity as a surrogate
marker for tumour burden. In a multivariate model dichotomising
number of metastatic sites into low (1 metastatic site) and high (2
sites), the number of ctDNA alterations detected was significant
(P<0.005, Supplemental Table 2).
Fig. 3. Gene variant distribution for the main targetable genes in metastatic breast cancer. Variant heatmaps for PIK3CA, ERBB2, and ESR1 are included. Frequency (count) of each
variant is shown in the legend in the bottom right corner. Greater diversity of PIK3CA and ERBB2 variants were observed as compared with ESR1. No copy number changes in ESR1
were present in the cohort. The most common single nucleotide variants (SNVs) for PIK3CA, ERBB2, and ESR1were the following: H1047R, S310F, and D538G, respectively.
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We evaluated the genomic profile and associated clinical data of
patients with metastatic breast cancer who underwent ctDNA testing
in a large cohort. The goals of the analysis were to identify the land-
scape of ctDNA across pathological subtypes, to evaluate the preva-
lence of clinically actionable alterations, to compare blood and tissue
NGS for patients with paired sequencing, and to assess similarities
between blood and imaging assessment for disease monitoring.
Here, we report several key findings from our analyses. First,
ctDNA evaluation was able to capture the landscape of alterations
including SNVs, indels, and fusions. Across the cohort, unique altera-
tions were detected in more than 80% of the genes evaluated. Fur-
thermore, the frequency and distribution of genes encountered
varied across the HR+, HER2+, and TNBC subtypes with TNBC patients
having a statistically higher MAF in our cohort, but not a higher num-
ber of alterations. When comparing alterations for patients with
paired blood and tissue sequencing, concordance was relatively high
with some expected differences between blood and tissue NGS due
to biological and technical factors in sampling. The capability of
ctDNA evaluation to capture spatial tumour heterogeneity (e.g. reflectTable 2.
Concordance of next-generation sequencing (NGS) between blood and tissue for the
10 most common alterations in the cohort. The 10 most common alterations in
decreasing frequency were the following: TP53, PIK3CA, ERBB2, ESR1, MYC, EGFR,
FGFR1, CCNE1, NF1, and ARID1A. Notably, the 80% agreement for EGFR was confined
to wild-type cases, while 95% of the samples classified as mutated through ctDNA
were wild-type based on tissue biopsy. Blood and tissue NGS from paired patient
samples were compared using Cohen kappa values with >0.7 indicating very high
concordance and >0.5 indicating moderate to high concordance.
Observed agreement Kappa 95% C.I. P
TP53 79.1% 0.5809 0.4061 0.7147 < 0.0001
PIK3CA 81.0% 0.5513 0.360 0.6988 < 0.0001
ERBB2 79.1% 0.3675 0.1572 0.5596 0.0001
ESR1 84.8% 0.4167 0.1808 0.6167 < 0.0001
MYC 80.0% 0.3860 0.1736 0.5770 < 0.0001
EGFR 80.0% 0.0541 0.1053 0.2352 0.1421
FGFR1 90.5% 0.6313 0.3984 0.7929 < 0.0001
CCNE1 83.8% 0.3014 0.0622 0.5153 0.0001
NF1 83.8% 0.1748 0.0131 0.4325 0.0325
ARID1A 89.5% 0.2979 0.0611 0.5753 0.0009tumour from multiple metastatic sites) and the convenience of serial
blood sampling reinforce the potential of this technique.
We also reported the frequency of clinically actionable alterations
that were encountered in our cohort. For example, in the HR+ cohort,
PIK3CA, ESR1, and ERBB2 gene alterations were detected at the fol-
lowing frequencies: 46%, 30%, and 14%, respectively. However, we
decided not to report a specific summative statistic, given that the
actionability of these alterations is largely dependant on the concur-
rent drug development pipeline and available drugs at the time of
analysis. At present, there is a Food and Drug Administration (FDA)
approved targeted agent for PIK3CA (alpelisib), while agents targeting
patients with ERBB2 mutations (e.g. neratinib) have demonstrated
clinical activity, but no current FDA approval for this indication
[17,2830]. Furthermore, in breast cancer, there is currently only
one FDA drug approval linked to a ctDNA companion diagnostic for a
PCR-based test to utilise alpelisib with the registry trial including
patients with PIK3CA mutations in exons 7, 9, and 20 [28,31]. In con-
trast, the diversity of alterations observed in our cohort in PIK3CA
reinforces the need to explore clinical benefit using drugs across a
broader range of SNVs. Data are also emerging that double PIK3CA
mutations increase sensitivity to these inhibitors, indicating the clini-
cal importance of assessing for multiple driver mutations in the same
gene, concurrently [32,33]. Further work is necessary to identify
PIK3CA mutations with decreased sensitivity to drugs targeting the
phosphoinositide 3-kinase pathway [34].
The most common genomic alterations encountered in our study
were similar to those reported in a large cohort of patients who
underwent tissue NGS sequencing with the most commonly
observed alterations in TP53 and PIK3CA [12]. The detection of PIK3CA
and ESR1 mutations in plasma were also similar to prior ctDNA stud-
ies focusing on single resistance mutations [8,14]. Our data also dem-
onstrate the complementary nature of blood and tissue NGS as 11.4%
of patients were found to have detectable gene alterations in PIK3CA
in ctDNA, but not tissue. With respect to ERBB2, the majority of these
mutations (59%) were detected in HR+ patients, indicating the need
to assess for resistance mutations in this population. However, our
findings also reinforce the current limitations with respect to detect-
ing copy number changes, such as ERBB2, in ctDNA compared to tis-
sue NGS, a finding which is consistent with prior work [20].
Additionally, there are emerging strategies for treating patients who
develop endocrine resistance with ESR1mutations [14,35,36]. Clinical
trials for matched molecular targets for many other genomic
Fig. 4. A,B ctDNA as a reflection of tumour burden on imaging. ctDNA were compared with CT or PET-CT imaging in close proximity with a median of 1.6 weeks (IQR 0.714.57)
between assessments. There was a significant association between mutant allele frequency (MAF) of the highest variant and number of sites of disease on imaging (Panel A,
P<0.0001, Mann Whitney U test) (N: 222). Similarly, a significant association was observed between number of detectable alterations (NDA) and number of metastatic sites (Panel
B, P<0.0001, MannWhitney U test) (N: 227).
A.A. Davis et al. / EBioMedicine 58 (2020) 102914 7alterations encountered in our sample are ongoing, including AKT and
DNA damage repair pathways, amongst many others.
While our study focused on a baseline ctDNA assessment, the reli-
able detection of alterations suggests that monitoring alterations in
the blood could identify genomic evolution and drug resistance to
potentially guide clinical management. Potential clinical utility of
ctDNA could include an initial assessment of alterations with known
drug targets, such as PIK3CA and ERBB2. In terms of treatment moni-
toring, a growing body of evidence has identified that changes in spe-
cific alterations or tumour burden, as indicated by ctDNA MAF,
correlates with treatment response [23,37,38]. This may enable mon-
itoring of specific alterations (e.g. PIK3CA changes in response to alpe-
lisib) or changes in MAF in response to systemic therapy. Here, we
add additional insight to this literature by associating findings on
imaging with ctDNA assessment. Specifically, MAF (e.g. tumour bur-
den) and genomic heterogeneity (e.g. number of alterations) in
ctDNA were both significantly associated with increasing number of
metastatic sites on imaging. Therefore, in our cohort, ctDNA evalua-
tion was a reflection of tumour burden on imaging, despite thecurrent inability for this technique to locate specific sites of metasta-
sis. Ongoing work is evaluating how serial ctDNA testing correlates
with imaging changes over time and whether particular clinical,
pathologic, and genomic profiles in blood may predict sites of metas-
tasis, prior to their occurrence.
There were several limitations of our study. First, this was a retro-
spective analysis and therefore prone to unknown bias, which we
attempted to limit by analysing consecutively enroled patients with
ctDNA testing. Second, blood sample collection was obtained per
standard clinical care, and there was inherent variability in the order-
ing practices of providers, although the vast majority of testing was
ordered at baseline assessment or at the time of clinical progression.
Third, the timeframe of blood and tissue NGS sequencing was not
aligned in all cases, which may have introduced greater discordance
into these analyses, and paired sequencing data were only available
for a subset of patients. In addition, some patients had tissue NGS
analysed from the primary tumour site, which may have introduced
greater discordance between blood and tissue. Fourth, the findings
reported here were based on ctDNA sequencing from a single NGS
8 A.A. Davis et al. / EBioMedicine 58 (2020) 102914assay at a single institution, and therefore may not apply to other
sequencing platforms, depending on the particular technical specifi-
cations of the assay. Furthermore, the inclusion of a relatively large
percentage of IBC patients may not be fully generalisable to non-aca-
demic referral centers.
In conclusion, our findings demonstrate the landscape of ctDNA in
metastatic breast cancer using one of the largest clinically annotated
datasets. Collectively, our data reinforce the genetic heterogeneity of
metastatic breast cancer that can be captured in blood, concordance
between blood and tissue NGS, the high prevalence of clinically
actionable alterations, and the potential to utilise ctDNA as a surro-
gate for tumour burden. Further studies are needed to independently
validate these findings, to compare dynamics of serial genomic test-
ing of metastatic breast cancer patients in the blood, and to incorpo-
rate ctDNA assays into novel clinical trial designs for patient
enrolment and stratification.
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